B of A Securities Downgrades Esperion Therapeutics to Underperform, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has downgraded Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and lowered the price target from $2.9 to $2.5.
June 20, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities has downgraded Esperion Therapeutics from Neutral to Underperform and lowered the price target from $2.9 to $2.5. This downgrade and reduced price target could negatively impact the stock price in the short term.
The downgrade from Neutral to Underperform by a major analyst like B of A Securities, along with a lowered price target, typically signals a lack of confidence in the company's near-term performance. This is likely to result in a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100